Overall, in addition to common toxicity of chemotherapy, the incidence of special toxicity associates with targeting VEGFR drugs could reflect its safety, including hypertension, bleeding or hemorrhage, arterial thromboembolic events (ATE), venous thromboembolic events (VTE), proteinuria, hand-foot syndrome, gastrointestinal (GI) perforation, renal failure, cardiac failure, and infusion-related reaction. This evidence concerns the gene KDR and Hand-foot syndrome.